Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2330811 in Moderate to Severe Crohn's Disease
NCT04151225Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of gsk2330811 in Crohn's disease (5 arms), sponsored by GSK. Primary endpoint: Percentage of participants with endoscopic response measured by SES-CD at 12 weeks. Planned start Apr 2021; status: withdrawn.
02
Drugs
gsk2330811
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04151225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151225.